103639-57-2

Basic information

• Product Name: (S)-2-(2-Hydroxyethyl)piperidine
• Synonyms: (S)-2-(2-Hydroxyethyl)piperidine;2-piperidiMethanol;2-Piperidineethanol, (2S)-;(S)-2-(Piperidin-2-yl)ethanol;(S)-2-(piperidin-2-yl)ethan-1-ol hydrochloride;2-Piperidineethanol, (S)-;2-[(2S)-piperidin-2-yl]ethanol
• CAS NO: 103639-57-2
• Molecular Formula: C₇H₁₅NO
• Molecular Weight: 129.2
• Product Categories: Amines;Chiral Reagents;Heterocycles
• Mol File: 103639-57-2.mol

Chemical Properties

• Melting Point: 60-62°C
• Boiling Point: 234.5±13.0 °C(Predicted)
• Appearance: /
• Density: 0.939±0.06 g/cm3(Predicted)
• Storage Temp.: Hygroscopic, -20°C Freezer, Under Inert Atmosphere
• PKA: 15.15±0.10(Predicted)
• CAS DataBase Reference: (S)-2-(2-Hydroxyethyl)piperidine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-(2-Hydroxyethyl)piperidine(103639-57-2)
• EPA Substance Registry System: (S)-2-(2-Hydroxyethyl)piperidine(103639-57-2)

Safety Data

• Hazardous Substances Data: 103639-57-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-2-(2-Hydroxyethyl)piperidine is used as a key intermediate in the preparation of a novel class of pyrazolopyrimidines. These pyrazolopyrimidines act as inhibitors of protein and checkpoint kinases, which are useful in the treatment and prophylaxis of Hepatitis C Virus (HCV) infection and other diseases such as cancer. (S)-2-(2-Hydroxyethyl)piperidine's unique structure and properties make it a valuable component in the development of innovative therapeutic agents.

InChI:InChI=1S/C7H15NO/c9-6-4-7-3-1-2-5-8-7/h7-9H,1-6H2/t7-/m0/s1

Upstream product

• 1484-84-0 2(RS)-(2-hydroxyethyl)piperidine 

Downstream Products

• 64625-19-0 (S)-2-(piperidin-2-yl)ethanoic acid 
• 190967-63-6 benzyl (2S)-2-(2-hydroxyethyl)piperidine-1-carboxylate 
• 779353-01-4 Dinaciclib 
• 856015-27-5 (S)-2-[2-(2,6-Dimethoxy-cyclohexa-2,5-dienyl)-ethyl]-piperidine 
• 199942-74-0 (S)-2-(2-hydroxy-ethyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 1374007-15-4 C₂₁H₃₅NO₃Si 
• 1374007-16-5 C₁₉H₃₄N₂O₃SSi 
• 1393456-04-6 C₁₉H₃₂N₂O₅SSi 
• 1393456-05-7 C₁₉H₂₁F₃N₄O₄S 
• 1374006-94-6 (S)-N-(4-((2-(2-hydroxyethyl)piperidin-1-yl)sulfonyl)phenyl)-1-methyl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide 
• 1374006-96-8 (S)-1-methyl-N-(4-((2-(2-morpholinoethyl)piperidin-1-yl)sulfonyl)phenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide 
• 2220184-50-7 (S)-2-(1-(6-(((6,7-difluoro-1H-benzo[d]imidazol-2-yl)methyl)amino)-9-isopropyl-9H-purin-2-yl)piperidin-2-yl)ethan-1-ol 

Relevant articles and documents

Total synthesis of (-)-senepodine G and (-)-cermizine C

(Chemical Equation Presented) An efficient, stereospecific synthesis of the alkaloids senepodine G (2) and cermizine C (1) has been completed using the BF3·Et2O-promoted stereospecific addition of Me2CuLi to α,β-unsaturated lactam 6 to provide lactam 3, the addition of MeMgBr followed by HCl to convert 3 to senepodine G (2) (six steps, 40% overall yield), and the stereospecific NaBH4 reduction of 2 to give cermizine C (1) (seven steps, 40% overall yield).

Expanded substrate scope and catalyst optimization for the catalytic kinetic resolution of N-heterocycles

The scope, reactivity, and selectivity of the chiral hydroxamic acid-catalyzed kinetic resolution of chiral amines are improved by a new catalyst structure and a more environmentally friendly reaction protocol. In addition to increasing selectivity across all substrates, these conditions make possible the resolution of N-heterocycles containing lactams or other basic functional groups that can inhibit the catalyst.

Process and intermediates for the synthesis of (3-alkyl-5-piperidin-1-yl-3,3a-dihydro-pyrazolo[1,5-a]pyrimidin-7-yl)-amino derivatives and intermediates

This application discloses a novel process to synthesize (3-alkyl-5-piperidin-1-yl-3,3a-dihydro-pyrazolo[1,5-a]pyrimidin-7-yl)-amino derivatives, and intermediates useful in the synthesis thereof. The subject (3-alkyl-5-piperidin-1-yl-3,3a-dihydro-pyrazolo[1,5-a]pyrimidin-7-yl)-amino derivatives are useful as cyclin-dependent kinase inhibitor compounds (CDK inhibitors) in pharmaceutical preparations.

Process for resolving chiral piperidine alcohol and process for synthesis of pyrazolo[1,5-a] pyrimidine derivatives using same

The present invention provides a method of resolving piperdin-yl-alkylene-alcohols, in high yield at high enantiomeric purity, for example 2-piperidin-2-yl-ethanol.

Pyrazolotriazines as kinase inhibitors

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]triazine compounds as inhibitors of kinases such as, for example, cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing

Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.